EN SV HOME SUSTAINABILITY COMMITMENT TO PATIENTS HUMANITARIAN AID Commitment to patients Patient centricity Humanitarian aid Responsible behaviour Code of Conduct Our Human Rights Statement Responsible sourcing Environmental footprint Transparency Disclosure of Payments to Healthcare Trade association membership Sustainability performance Humanitarian aid Together with Sanofi, we intend to donate up to 1 billion international units (IU) of factor replacement for use in developing countries. More than 75 per cent of people with haemophilia around the world have limited or no access to diagnosis and treatment, particularly in the developing world. People with severe haemophilia in these countries often do not survive to adulthood; for those who do, life often entails severe disability, isolation and chronic pain. The World Federation of Hemophilia (WFH) Humanitarian Aid Program helps address the lack of access to care and treatment by providing much-needed support for people with inherited bleeding disorders in developing countries. In 2020, we announced an extension of our support for the WFH Humanitarian Aid Program with an additional donation of up to 500 million international units (IU) of factor therapy for humanitarian use, fulfilling the 2014 pledge to donate up to an unprecedented 1 billion IU over a 10-year period. Since the initial pledge in 2014, more than 538 million IU have been donated and over 17,330 people with haemophilia have been treated with factor donated by Sobi and Sanofi. Both companies are recognised by the WFH as Founding Visionary Partners of this programme. “For lasting change to become a reality, we need to recognise that access to treatment is a fundamental human right. We are proud to do our part to address this critical health issue, in partnership with Sanofi,” says Guido Oelkers, CEO and President of Sobi. “Partnership in reaching the goals is essential. We are pleased to see others following our lead and encourage more companies to join in the shift that the WFH and their local organisations have made possible and that we together can carry forward. Only through a broad long-term commitment to increase awareness, knowledge and access to treatments will the effect of our donation be sustainable and withstanding.” Read stories about some of the people who have been impacted by the donation. Steve’s story – His scar opens for discussions about haemophilia Salomon’s story – Haemophilia and soccer in Kenya Changing lives in Vietnam See more films about the impact here. Read more WFH Humanitarian Aid Program makes surgery recovery possible in Pakistan Glenn Pierce discusses WFH Humanitarian Aid Program efforts in Africa About us At a glance Rare diseases Therapeutic areas Haematology Immunology Specialty Care portfolio Investors Reports & presentations Share information Calendar Career Open positions Meet our employees Media Press releases Gallery Sobiplay Sitemap Cookie Policy Privacy Policy Terms of use Cookies Settings © Swedish Orphan Biovitrum AB (publ) Reg. no. 556038-9321 This website uses cookies By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. Accept All Cookies Cookies Settings